Arthur Kuan, CG Oncology CEO

CG On­col­o­gy reels in $105M crossover for po­ten­tial late 2024 blad­der can­cer drug fil­ing

CG On­col­o­gy, out to treat blad­der can­cer pa­tients left be­hind by the short­age of Mer­ck’s stan­dard BCG ther­a­py or didn’t ben­e­fit from it in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.